Your session is about to expire
← Back to Search
Ketone Monoester
Ketone Monoester for Heart Failure (KINETICS2 Trial)
Phase 2
Waitlist Available
Research Sponsored by University of Aarhus
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Inclusion criteria: Chronic HF: NYHA class II-III, left ventricular ejection fraction (LVEF) \<40%
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 hours
Summary
We aim to investigate the hemodynamic effects of weight-adjusted dosing of ketone monoester en patients with chronic heart failure.
Eligible Conditions
- Heart Failure
- Ketosis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Cardiac Output (L/min)
Secondary study objectives
Blood Ketones
Blood pH
Left Ventricular Ejection Fraction
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Ketone MonoesterExperimental Treatment1 Intervention
Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US) 0.5 g/kg (max 50 g)
Group II: Ketone Monoester in presence of low-dose insulin clampActive Control1 Intervention
Same as experimental arm, but in the presence of a low-dose insulin clamp to suppress free fatty acid metabolism
Group III: Placebo TreatmentPlacebo Group1 Intervention
Maltodextrin-based placebo (Science In Sport, UK) in isocaloric dose to the experimental arm.
Find a Location
Who is running the clinical trial?
University of AarhusLead Sponsor
1,413 Previous Clinical Trials
14,461,083 Total Patients Enrolled
32 Trials studying Heart Failure
5,942,653 Patients Enrolled for Heart Failure
Share this study with friends
Copy Link
Messenger